Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity  by Jones, Sarah et al.
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Protein-coated  microcrystals  (PCMCs)  were  investigated  as  potential  vaccine  formulations  for  a  range  of
model  antigens.  Presentation  of  antigens  as  PCMCs  increased  the  antigen-speciﬁc  IgG  responses  for  all
antigens  tested,  compared  to soluble  antigens.  When  compared  to  conventional  aluminium-adjuvanted
formulations,  PCMCs  modiﬁed  with calcium  phosphate  (CaP)  showed  enhanced  antigen-speciﬁc  IgG
responses  and  a decreased  antigen-speciﬁc  IgG1:IgG2a  ratio,  indicating  the induction  of  a more  bal-
anced  Th1/Th2  response.  The  rate  of antigen  release  from  CaP  PCMCs,  in  vitro,  decreased  strongly  withicroparticles
alcium phosphate
hagocytosis
djuvant
increasing  CaP loading  but their  immunogenicity  in  vivo was  not  signiﬁcantly  different,  suggesting  the
adjuvanticity  was  not  due  to a depot  effect.  Notably,  it was  found  that  CaP  modiﬁcation  enhanced
the  phagocytosis  of  ﬂuorescent  antigen-PCMC  particles  by  J774.2  murine  monocyte/macrophage
cells  compared  to  soluble  antigen  or  soluble  PCMCs.  Thus,  CaP  PCMCs  may  provide  an  alternative
to  conventional  aluminium-based  acellular  vaccines  to provide  a  more  balanced  Th1/Th2  immune
response.©  2014  The  Authors.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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oom  temperature.
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. Introduction
Conventional aluminium-containing adjuvants have been used
n vaccine formulations for decades but promote poor induction
f Th1 or cell-mediated immunity [1,2] and require refrigeration
uring transportation and storage. Approximately 50% of vaccines
re discarded globally, largely due to cold chain disruption [3,4].
herefore, a major objective of vaccine formulation t is to develop
 safe, immunogenic composition which addresses the issues of
mmune bias and stability.
Protein-coated microcrystals (PCMCs) are a recent advance in
accine formulation [5] and have the potential to by-pass the
old chain. Originally developed to stabilise enzymes for industrial
pplications [5–9], PCMCs are formed by rapid co-precipitation of
rotein(s) with an amino acid or sugar, producing particles with
n inert core microcrystal coated with protein(s) [6,8,9]. Vaccine
ntigens, loaded onto PCMCs, exhibited much higher resistance to
eat stress compared to native antigens [5,7]. These reports used
CMC formulations which were instantly soluble in aqueous buffer
5–9]. In this study, novel sustained-release PCMCs have been used
hich are poorly soluble due to modiﬁcation of their outer surface
ith sparingly soluble CaP. CaP served as an adjuvant in some early
cellular vaccines [10,11], and is well-tolerated in man  [11–16]. CaP
lso enhances Th1-biased immunity although this may  be antigen-
ependent [11,17,18]. Here, the immunogenicity of CaP-modiﬁed
CMCs loaded with different model antigens was  investigated. DT,
 formaldehyde-toxoided antigen [19–21], and BSA have been used
xtensively as model antigens when validating new vaccine formu-
ations [22–25].
. Materials and methods
.1. Source of antigens
The DT preparation was the 2nd international standard for use
n ﬂocculation tests (02/176, NIBSC, UK). CyaA* was puriﬁed and
haracterised as described previously [26–28]. BSA was  from Sigma
nd BSA-FITC was from Life Technologies, UK.
.2. PCMC preparation
All reagents were of the highest grade available and were used
t rt. The aqueous solution was prepared in endotoxin-free, ster-
le water (Sigma) and contained 30 mg/ml  l-glutamine as the core
omponent of the PCMCs, trehalose and the test antigens, sufﬁcient
o give ﬁnal loadings of 10% and 0.2–0.4%, respectively, in the PCMC
reparation. To precipitate PCMCs, 3 ml  of the aqueous solution
as added drop-wise to 60 ml  of rapidly stirred isopropanol and
tirring continued for 1 min  at 1500 rpm. For CaP-modiﬁed PCMCs,
he required concentration of NaH2PO4 was included in the aque-
us solution and CaCl2 was included in the isopropanol at a 2-fold
olar excess compared to NaH2PO4. PCMCs were collected by vac-
um ﬁltration onto PVDF hydrophilic 0.45 m ﬁlters (Millipore, UK)
nd dried overnight for storage as a dry powder.
.3. Quantiﬁcation of antigen loading by ELISA
PCMCs were dissolved at 10 mg/ml  in sodium citrate buffer
50 mM sodium citrate, 20 mM Tris, 1 mM EDTA, pH6.8]. The PCMC
olution was diluted 1:3 v/v in carbonate coating buffer [15 mM
a2CO3, 30 mM NaHCO3, pH9.5] and serially diluted in a ﬂat-
ottom 96-well ELISA plate (MAXISorp, Nunc, UK). Plates were
ncubated overnight at 4 ◦C prior to washing 3 times in PBST. Non-
peciﬁc binding was blocked by addition of 100 l/well of block-B
nd incubation for 1 h at 37 ◦C. For BSA-containing PCMCs, block-G
as used in place of block-B. After further washing, samples were (2014) 4234–4242 4235
incubated (2 h, 37 ◦C) with 50 l/well of the appropriate primary
antibody [anti-DT (NIBSC, 1/1000), anti-CyaA* (in-house, 1/500)]
or anti-BSA (Sigma, 1/1000)] diluted in the appropriate blocking
buffer. After washing, 50 l/well of peroxidase-conjugated sec-
ondary antibody (Sigma) diluted 1/1000 in the appropriate blocking
buffer was added and plates incubated for 1.5 h at 37 ◦C. Plates were
washed again and protein binding was  visualised using 50 l/well
of O-phenylene-diamine. After incubation for 10–15 min  at rt,
colour development was  stopped with 3 M HCl and absorbance at
492 nm was measured. Protein loading onto PCMCs was  quantiﬁed
by comparison to a stock antigen standard curve.
2.4. Determination of PCMC morphology
For SEM, dry PCMCs were gold-plated prior to visualisation with
a JEOL6400 electron microscope operating at 6 kV.
2.5. Characterisation of antigen release in vitro
PCMCs were suspended at 10 mg/ml  in 1.5 ml  of either 0.1 mM
sodium citrate (pH 6.0) or PBS and incubated at rt or 37 ◦C with gen-
tle agitation. At intervals, the PCMC suspension was centrifuged for
1 min  at 2400 × g and 1 ml  of supernate removed to determine pro-
tein release. More buffer was then added to the pelleted PCMCs to
readjust the volume to 1.5 ml  and the incubation continued. Super-
nates were stored at −20 ◦C prior to quantiﬁcation of protein release
by ELISA as described above.
2.6. Adsorption of antigens to Al(OH)3
Soluble antigens were dissolved in sterile PBS containing
10% Al(OH)3 (A8222, Sigma), mixed thoroughly and incubated
overnight at 4 ◦C. Adsorbed antigens were then used for immun-
isation.
2.7. Immunisation of mice
Groups of 8 inbred, female 6–8 week old NIH mice (Harlan, UK)
were injected subcutaneously at days 0 and 28 with 0.5 ml  volumes
of the desired formulation or PBS as a control. Immediately prior
to immunisation, the required doses of PCMCs were suspended
in sterile PBS. Mice were sampled for sera at 28 d and 42 d post-
immunisation, as described previously [28]. All animal experiments
were performed under UK Home Ofﬁce License and in accordance
with EU Directive 2010/63/EU.
2.8. Determination of antigen-speciﬁc serum IgG titres
Antigen-speciﬁc IgG, IgG1 and IgG2a titres were determined
using ELISA as described previously [26] with the use of block-G
when determining anti-BSA responses. Geometric mean titres were
calculated by comparison to reference sera.
2.9. Culture of J774.2 cells
Murine monocyte/macrophage J774.2 cells were maintained in
75 cm2 tissue-culture ﬂasks (Corning, UK) (37 ◦C, 5% CO2) in com-
plete RPMI [cRPMI; RPMI 1640 medium (Life Technologies, UK), 10%
foetal calf serum (Sigma), 10 mM l-glutamine, 100 U/ml penicillin
and 100 g/ml streptomycin (Life Technologies, UK)].
2.10. Uptake of PCMCs by J774.2 cells2.10.1. Flow cytometry
Each well of a 24-well tissue-culture plate (Corning, UK)  was
supplemented with 106 J774.2 cells and incubated (2 h, 37 ◦C, 5%
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Fig. 1. Effect of CaP on the morphology of PCMCs and the rate of antigen release. Panels A–C: PCMCs were loaded with 0.2% (w/w) DT and either 0% CaP (panel A), 6% CaP
(panel B) or 20% CaP (panel C). Dried PCMC preparations were gold-plated and visualised by SEM at 5000 × magniﬁcation. Scale bar = 5 m.  Images are representative of at
least  n = 2 independent SEM preparations. Panel D: PCMCs were prepared with 0.2% loading of each of DT and CyaA* and resuspended at 10 mg/ml  in 1 mM sodium citrate,
pH  6.0 at room temperature with gentle agitation. Samples were taken at 1 h intervals and the protein release quantiﬁed by ELISA for 0% CaP (closed squares), 6% CaP (open
squares) and 20% CaP (triangles) PCMCs. *p < 0.05 0% CaP vs. 6% CaP PCMCs, ++p < 0.01 0% CaP vs. 20% CaP PCMCs, +++p < 0.001 0% CaP vs. 20% CaP PCMCs, #p < 0.05 6% CaP vs.
20%  CaP PCMCs, ##p < 0.01 6% CaP vs. 20% CaP PCMCs. Panel E: PCMCs were prepared with 0.4% loading of BSA-FITC and resuspended at 10 mg/ml in sterile PBS at 37 ◦C with
gentle  agitation. Samples were taken at intervals and BSA-FITC release in the supernatant determined by ELISA for 0% CaP (squares), 6% CaP (circles), 12% CaP (triangles) and
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P0%  CaP PCMCs (crosses). Results are representative triplicate measurements of at 
O2) after which the medium was replaced with 1 ml/well of fresh
RPMI. A 5 mg/ml  suspension of 0–20% CaP PCMCs loaded with
.4% BSA-FITC or the equivalent concentration of soluble BSA-FITC
ere prepared in cRPMI. A 0.5 ml  aliquot was added to each well
nd incubated (1 h, 37 ◦C, 5% CO2) whilst protected from light. To
top uptake, cells were washed twice with ice-cold PBS and sus-
ended in 1 ml  of ice-cold PBS. Cells were centrifuged for 10 min  at
18 × g, the resultant pellet suspended in 4 ml  of ﬁxing solution [1%
ormaldehyde in PBS] and samples stored at 4 ◦C whilst protected
rom light. Uptake of ﬂuorescent particles was determined using a
ACSCanto II ﬂow cytometer (BD Biosciences).
.10.2. Confocal laser-scanning microscopy
Sterile glass coverslips were coated with 0.2% gelatine in PBS
nd air-dried. An aliquot of 106 J774.2 cells in 2 ml of cRPMI
as added to each well (24-well tissue-culture plate) contain-
ng coated coverslips and incubated (3 h, 37 ◦C, 5% CO2) for cell
ttachment. Cells were then incubated (1 h, 37 ◦C, 5% CO2) with
he appropriate antigen formulation and washed twice with PBS-A,
hen ﬁxed (300 l/well, 4% paraformaldehyde in PBS-A) and incu-
ated (20 min, rt). Cells were permeabilised by incubation with
BS-A containing 0.2% BSA and 0.2% Triton X-100 and secondary = 3 independent experiments.
incubation with PBS-A containing 5% BSA. After washing, the actin
cytoskeleton was  stained with AlexaFluor594-conjugated phal-
loidin (Life Technologies, UK) for 5 min  prior to nuclear staining
with 4′,6-diamidino-2-phenylindole (DAPI) for 3 min. After wash-
ing, the coverslips were mounted onto glass microscope slides
and cell ﬂuorescence visualised using a Leica SP2 AOBS laser-
scanning confocal microscope (40×, NA 1.25 oil immersion lens).
Images were analysed using IMARIS software v7.4.2 (Bitplane,
Switzerland).
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism5
software. Gaussian distribution of the data was assessed using
the D’Agostino and Pearson omnibus normality test. Responses
between several groups were compared by one-way analysis of
variance (ANOVA) with Tukey’s, Bonferroni’s or Dunn’s correc-
tion, as appropriate. Where data failed to pass the normality
test, non-parametric comparison between several groups was by
the Kruskal–Wallis test. Comparison of data between two groups
was performed using Student’s t-test. Statistical signiﬁcance was
deﬁned as p < 0.05.
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Fig. 2. Effect of PCMC formulation on the immunogenicity of soluble antigens. 8
mice/group were immunised subcutaneously with 12 g/dose DT at 0 d, adminis-
tered as either PCMCs or soluble antigen prior to boosting at 28 d. Anti-DT IgG titres
were determined by ELISA in serum taken at 28 d and 42 d post-immunisation.
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aata represent mean log10{geometric mean anti-DT IgG titre (IU/ml)} ± SEM for
 = 8 mice/group ***p < 0.001. Results are representative of n ≥ 2 independent exper-
ments.
. Results
.1. Inclusion of CaP alters PCMC morphology and signiﬁcantly
ecreases antigen release rate in vitro
SEM showed that soluble PCMCs loaded with antigen without
aP (0% CaP PCMCs) were planar, irregular discs (Fig. 1A) but, as the
aP loading increased, the particles became more regular rod-like
tructures (Fig. 1B and C). This change in morphology was  antigen-
ndependent over the 0.2–0.4% antigen loading used (not shown).
The in vitro release of antigen from different CaP PCMC for-
ulations was compared by suspending the particles in 0.1 mM
odium citrate, pH 6.0 at rt. PCMCs without CaP and loaded simul-
aneously with DT and CyaA* released DT almost instantaneously
hilst the 6% and 20% CaP PCMCs displayed progressively delayed
ntigen release (Fig. 1D). Similar results were obtained for all anti-
ens and combinations tested, indicating that the phenomenon was
ot antigen-speciﬁc (not shown). BSA-FITC release from PCMCs
uspended in PBS at 37 ◦C was investigated as a more physiolog-
cally relevant model. BSA-FITC release from PCMCs without CaP
as extremely rapid but was signiﬁcantly slower with CaP PCMCs
Fig. 1E).
.2. PCMCs are more immunogenic than soluble antigen alone
Subcutaneous injection of mice with PCMCs loaded with DT in
he absence of CaP induced signiﬁcantly higher anti-DT IgG titres
han the equivalent soluble antigen at both 28 d and 42 d (Fig. 2).
imilar effects were seen with the other antigens indicating that
his response was not antigen-speciﬁc (data not shown).
.3. CaP modiﬁcation increases the immunogenicity of antigens
oaded onto PCMCs
Whilst formulation into PCMCs enhanced the immune response
o DT, it was likely that surface modiﬁcation with CaP would further
nhance antigen-speciﬁc IgG titres. Mice were immunised with 0%,
% or 20% CaP PCMCs loaded with DT, DT + CyaA* or BSA. CaP PCMCs
nhanced the antigen-speciﬁc IgG response to DT and BSA at 28 d
nd 42 d post-immunisation (Fig. 3). For PCMCs loaded with DT (2014) 4234–4242 4237
alone, CaP modiﬁcation increased serum anti-DT IgG titres prior to
boosting (Fig. 3A) but the effect was  more pronounced after boost-
ing (Fig. 3B). Inclusion of CyaA* did not alter the adjuvant effect of
CaP on the anti-DT IgG response at 28 d (Fig. 3C) and 42 d (Fig. 3D).
The adjuvant activity of CaP was not conﬁned to DT, as CaP PCMCs
also promoted an increase in anti-BSA IgG titres at 28 d (Fig. 3E)
and 42 d (Fig. 3F).
3.4. CaP PCMCs alter the antigen-speciﬁc Th1/Th2 response
Serum antigen-speciﬁc IgG1 and IgG2a titres were determined
in order to assess whether CaP modiﬁcation altered the Th1/Th2
bias. In mice, a decreased IgG1:IgG2a ratio is associated with a Th1-
biased immune response [29]. Adsorption of DT to Al(OH)3 resulted
in a high IgG1 response (Fig. 4A) and a high anti-DT IgG1:IgG2a
ratio (Fig. 4C) compared to soluble antigen or PCMC formulations.
Increasing CaP loading increased both the anti-DT IgG1 and IgG2a
titres (Fig. 4A and B) but the overall effect was to decrease the anti-
DT IgG1:IgG2a ratio (Fig. 4C). Modiﬁcation with CaP signiﬁcantly
increased the anti-BSA IgG1 and IgG2a titres (Fig. 4D and E) but
decreased the anti-BSA IgG1:IgG2a ratio compared to soluble (0%
CaP) PCMC formulations (Fig. 4F).
3.5. CaP loading does not affect the duration or magnitude of the
antibody responses
The results above demonstrated that CaP modiﬁcation had
an adjuvant effect on PCMC-induced antigen responses in vivo,
although increasing the CaP loading from 6 to 20% did not have a
signiﬁcantly consistent dose-dependent effect. To investigate this
further, mice were immunised with a single dose of 0%, 6%, 12%
or 20% CaP PCMCs loaded with 6 g/dose each of DT and CyaA*
and the kinetics of the serum antigen-speciﬁc IgG responses deter-
mined up to 84 d post-immunisation. Mice immunised with equal
amounts of 6% and 20% CaP PCMCs were also included to investi-
gate any prime/boost effect arising from fairly rapid antigen release
from 6% CaP PCMCs and a more prolonged depot effect of 20% CaP
PCMCs. The adjuvant effect of including CaP in PCMCs was  con-
ﬁrmed for both antigens (Table 1). This was particularly marked
for the anti-CyaA* response as only one mouse in the 0% CaP group
produced a detectable anti-CyaA* IgG titre at each time point inves-
tigated. Increasing the CaP content did not signiﬁcantly further
increase the antigen-speciﬁc IgG titres or alter the duration of anti-
body response. The attempted prime-boost formulation failed to
enhance immunogenicity compared to other CaP PCMC formula-
tions.
3.6. CaP modiﬁcation promotes phagocytosis of PCMCs
J774.2 cells were incubated with equal amounts of either soluble
BSA-FITC or BSA-FITC formulated as 0% or 8% CaP PCMCs. Uptake
of ﬂuorescent antigen was  visualised by confocal laser-scanning
microscopy (Fig. 5, panels A–C) and quantiﬁed by ﬂow cytometry
(panels D–F). Confocal microscopy showed that soluble BSA-FITC
was poorly phagocytosed, with J774.2 cells containing low levels
of ﬂuorescence (Fig. 5A). In contrast, loading BSA-FITC onto PCMCs
increased phagocytosis, with cells displaying punctate regions of
green ﬂuorescence (Fig. 5B) and this was further enhanced with
CaP PCMCs (Fig. 5C). These observations were conﬁrmed by ﬂow
cytometry. The P2 daughter population was derived from the par-
ent population P1. The increase in MFI  of the P2-gated population
of the cells upon exposure to BSA-FITC PCMCs (Fig. 5E) and the
further increase in the presence of CaP-modiﬁed PCMCs (Fig. 5F)
indicates a greater phagocytosis of these particles compared to
soluble BSA-FITC (Fig. 5D).
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Fig. 3. Effect of PCMC formulation on serum antigen-speciﬁc IgG responses. Panels A–D: 8 mice/group were immunised subcutaneously with 12 g/dose DT formulated as
0%,  6% or 20% CaP PCMCs in the absence (panels A and B) or presence of CyaA* (panels C and D) at 0 d and boosted with equal doses at 28 d. Serum anti-DT IgG responses were
determined at 28 d (panels A and C) and 42 d (panels B and D) post-immunisation by ELISA. Panels E and F: 8 mice/group were immunised subcutaneously with 8 g/dose
BSA  formulated as 0%, 6% or 20% CaP PCMCs at 0 d and boosted with equal doses at 28 d. Serum anti-BSA IgG responses were determined at 28 d (panel E) and 42 d (panel F)
post-immunisation by ELISA. Data represent mean log10{geometric mean antigen-speciﬁc IgG titres} ± SEM for n = 8 mice/group *p < 0.05, **p < 0.01, ***p < 0.001. Results are
representative of n ≥ 2 independent experiments.
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Fig. 4. Effect of CaP loading on serum antigen-speciﬁc IgG1:IgG2a ratios. Panels A–C: 8 mice/group were immunised subcutaneously with DT 12 g/dose formulated as
soluble antigen, 0% CaP PCMCs, 6% CaP PCMCs, 20% CaP PCMCs or adsorbed to Al(OH)3 and boosted with equal doses at 28 d. Serum anti-DT IgG1 (panel A) and IgG2a titres
(panel  B) were determined at 42 d post-immunisation by ELISA. The IgG1:2a ratios for matched serum samples were also determined (panel C). Panels D–F: 8 mice/group
were  immunised subcutaneously with 8 g/dose BSA formulated as 0% CaP PCMCs, 6% CaP PCMCs or 20% CaP PCMCs and boosted with equal doses at 28 d. Serum anti-BSA
IgG1  (panel D) and IgG2a (panel E) responses were determined at 42 d post-immunisation by ELISA. The IgG1:2a ratios for matched serum samples were also determined
(panel  F). Data represent mean log10{geometric mean antigen-speciﬁc IgG titres} ± SEM for n = 8 mice/group *p < 0.05, **p < 0.01, ***p < 0.001. Results are representative of
n  ≥ 2 independent experiments.
4
t
m
C. DiscussionThese results, in combination with published data, demonstrate
hat PCMC formulations are suitable for vaccine applications and
ay  address problems associated with current vaccines. Moreover,
aP PCMCs were shown to be immunogenic and to promote a moremixed Th1/Th2 response in comparison to traditional formulations
and to soluble PCMCs [5,7].Modiﬁcation of the surface of PCMC with an outer layer of
CaP altered the particle morphology from planar discs to rod-like
structures and signiﬁcantly decreased the rate of antigen release
in vitro. PCMCs without CaP released antigen almost immediately
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Fig. 5. Effect of CaP modiﬁcation on phagocytosis by macrophages. The ﬁgure is a representative result for confocal laser-scanning microscopy and ﬂow cytometry of n ≥ 2
independent experiments. J774.2 cells were incubated with 20 g/ml soluble BSA-FITC antigen (panels A and D), 0% CaP BSA-FITC PCMCs (panels B and E) and 8% CaP BSA-FITC
PCMC  (panels C and F) for 1 h at 37 ◦C in an atmosphere of 5% (v/v) CO2. Cells treated under identical conditions without incubation with antigen were used as negative
controls in all experiments. Uptake of ﬂuorescent antigen was visualised by confocal laser-scanning microscopy (panels A–C, scale bars = 10 m)  and quantiﬁed by ﬂow
cytometry (panels D–F). Confocal image stacks of each sample were collected for individual emission/detection channels and a composite image formed from data from
multi-channels. Images were analysed using IMARIS software v7.4.2 (Bitplane, Switzerland) [green, target protein; blue, nucleus; and red, F-actin of cytoskeleton]. For clarity,
each  plate is presented showing red/blue/green ﬂuorescence (A1-C1) and also as only blue/green ﬂuorescent channels (A2-C2). The ﬂow cytometry (panels D–F) shows the
mean ﬂuorescence intensity (MFI) of the P2 daughter population derived from a live cell gated parent population (P1). (For interpretation of the references to color in ﬁgure
legend,  the reader is referred to the web version of the article.)
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on aqueous buffers whereas increasing the CaP loading progres-
ively decreased the rate of antigen release. This is consistent with
elease being controlled by dissolution of an outer layer of CaP,
he thickness of which is expected to increase with CaP loading.
his suggests that CaP PCMCs would potentially show enhanced
mmunogenicity due to a depot effect in vivo as has been proposed
or other adjuvants [2,15].
Surprisingly, mice immunised with DT formulated into soluble
CMCs showed enhanced immunogenicity compared to soluble DT
ntigen. The in vitro solubility data indicated that this enhanced
mmunogenicity was not due to a depot effect. Instead it may
e due to the high local concentration of l-glutamine arising
rom solubilisation of the PCMC core, since l-glutamine has been
hown to enhance immune function [30–33]. Consistent with pub-
ished data [10,11,17,34], CaP acted as an adjuvant in this study
nd signiﬁcantly enhanced CaP PCMC-induced antigen-speciﬁc IgG
itres compared to soluble PCMCs. The adjuvant effect of CaP and
luminium-based adjuvants has been attributed to their antigen
epot effect [2,15]. However, the rate of antigen release from CaP
CMCs had no signiﬁcant effect on the magnitude or duration of
he antibody response and corroborates a growing body of evi-
ence that the activity of traditional adjuvants is independent
f a depot effect [35–37]. It should be noted that no signiﬁcant
ecrease in antigen-speciﬁc IgG titre was observed for any formu-
ation tested up to 84 d post-immunisation. However investigation
f the antibody response for longer time periods might highlightdifferences between the different formulations. CaP PCMC pro-
moted a decrease in antigen-speciﬁc IgG1:IgG2a ratio compared to
Al(OH)3, indicating a more mixed Th1/Th2 immune response. Sim-
ilar results have been obtained in other studies as a result of both
CaP inclusion [17,38] and formulation into microparticle vaccines
[39–41].
As the adjuvant effect arising from surface modiﬁcation of PCMC
with CaP was independent of CaP loading, we hypothesised that
the morphology of CaP PCMCs may  be important for their adjuvant
activity. PCMCs are of suitable size and morphology to be phagocy-
tosed by immune cells [42] and phagocytosis of latex microspheres
by monocytes promotes their differentiation to functional dendritic
cells and subsequent immune priming in the draining lymph node
[43]. Formulation into PCMCs without CaP enhanced phagocytosis
of BSA-FITC by J774.2 cells, possibly due to enhanced cell function
arising from the l-glutamine released from the core component of
the soluble PCMCs [30–33]. However, the phagocytosis of BSA-FITC
was clearly further enhanced by formulation into CaP PCMCs. Thus,
CaP PCMCs may  exert their adjuvant effect, at least in part, through
enhanced uptake of antigen by tissue phagocytes and subsequent
enhancement of immune priming. However, further studies are
needed to determine the precise mechanism by which CaP PCMCs
exert their adjuvant effect in vivo.
Combined with published data [5,7], our results indicate that
CaP PCMCs represent a useful platform by which to progress future
vaccine formulation.
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